GET THE APP

..

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Natarajan Ranganathan

Clinical Research & Development, Kibow Therapeutics, Inc 4781 West Chester Pike, Newtown Square, PA 19073, USA

Publications
  • Mini Review   
    Targeting Inflammation to Slow CKD Progression- Role of Gut Microbiome Based Therapy
    Author(s): Emmanuel Anteyi*, Natarajan Ranganathan and Usha Vyas

    Chronic Kidney Disease (CKD) is a worldwide public health problem associated with high morbidity, mortality, and socioeconomic burden. Despite recent advances in pathogenesis and effective Standard of Care (SOC) therapy, the incidence of end stage renal disease remains high, attributed to the complex and diverse pathophysiological pathways in progression of CKD. Among the many pathogenetic pathways, inflammation plays the most central role in disease progression and related complications. Current SOC treatment to slow CKD progression has not adequately addressed these complex processes as a result of persistence of low-grade inflammation occurring at all stages of CKD. Previous attempts to address the inflammatory pathway with specific anti-inflammatory agents were, in certain cases discontinued for reasons ranging from drug safety to efficacy concerns, and bus.. Read More»
    DOI: 10.37421/2161-0959.2024.14.481

    Abstract HTML PDF

Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward